|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.95 CHF | -0.26% |
|
+0.90% | -1.97% |
| 12-02 | Kuros Biosciences Enrolls First Patient in Study of Synthetic Bone Graft for Hindfoot, Ankle Fusions | MT |
| 16/10/25 | Kuros Biosciences AG Raises earnings Guidance for the Year 2025 | CI |
| Capitalization | 1.06B 1.32B 1.14B 984M 1.83B 119B 1.96B 12.16B 4.78B 56.93B 4.94B 4.84B 209B | P/E ratio 2025 * |
135x | P/E ratio 2026 * | 69.3x |
|---|---|---|---|---|---|
| Enterprise value | 1.03B 1.29B 1.11B 960M 1.79B 116B 1.92B 11.86B 4.67B 55.53B 4.82B 4.72B 204B | EV / Sales 2025 * |
6.93x | EV / Sales 2026 * | 5.1x |
| Free-Float |
67.49% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Kuros Biosciences AG
More press releases
More news
| 1 day | -0.26% | ||
| 1 week | +0.90% | ||
| Current month | -1.97% | ||
| 1 month | -3.37% | ||
| 3 months | -17.41% | ||
| 6 months | -7.74% | ||
| Current year | -1.97% |
| 1 week | 25.8 |  | 28.02 |
| 1 month | 25.8 | | 28.44 |
| Current year | 25.8 | | 28.42 |
| 1 year | 14 | | 34.2 |
| 3 years | 1.11 | | 34.2 |
| 5 years | 1.11 | | 34.2 |
| 10 years | 1.11 | | 38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christopher Fair
CEO | Chief Executive Officer | 56 | 11/10/2023 |
Joost de Bruijn
CEO | Chief Executive Officer | 60 | 03/12/2017 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 16/02/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 13/06/2018 | |
Joost de Bruijn
BRD | Director/Board Member | 60 | 13/06/2018 |
Oliver Walker
BRD | Director/Board Member | 57 | 13/06/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.26% | +0.90% | +15.87% | +1,557.85% | 1.32B | |
| +2.09% | +2.60% | +11.01% | +94.00% | 49.52B | |
| +0.15% | +5.49% | +94.37% | +13.80% | 44.32B | |
| -2.56% | -6.46% | +126.88% | +718.87% | 33.97B | |
| -2.80% | +7.30% | -6.69% | -26.87% | 26.62B | |
| +1.52% | +0.50% | +43.76% | -21.45% | 20.71B | |
| -0.60% | +7.34% | +124.24% | -46.17% | 21.22B | |
| -0.74% | -5.17% | +112.47% | +148.97% | 14.4B | |
| +0.72% | -0.55% | +196.50% | - | 14.07B | |
| -2.15% | -8.28% | -5.11% | +259.79% | 13.32B | |
| Average | +0.79% | +0.12% | +71.33% | +299.86% | 23.95B | |
| Weighted average by Cap. | +1.07% | +0.91% | +69.90% | +156.20% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 149M 186M 160M 139M 258M 16.77B 277M 1.71B 674M 8.02B 696M 682M 29.41B | 198M 246M 212M 184M 342M 22.23B 367M 2.27B 893M 10.63B 923M 904M 38.99B |
| Net income | 9.2M 11.46M 9.87M 8.56M 15.92M 1.04B 17.08M 106M 41.59M 495M 42.97M 42.1M 1.82B | 18M 22.42M 19.31M 16.75M 31.15M 2.03B 33.42M 207M 81.38M 969M 84.08M 82.36M 3.55B |
| Net Debt | -26M -32.39M -27.9M -24.19M -45M -2.93B -48.27M -299M -118M -1.4B -121M -119M -5.13B | -51M -63.53M -54.73M -47.45M -88.27M -5.74B -94.69M -586M -231M -2.74B -238M -233M -10.07B |
More financial data
* Estimated data
Employees
158
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 26.94 CHF | -0.30% | 51,661 |
| 15/01/26 | 27.02 CHF | -0.52% | 111,916 |
| 14/01/26 | 27.16 CHF | -0.88% | 152,102 |
| 13/01/26 | 27.40 CHF | +5.38% | 315,497 |
| 12/01/26 | 26.00 CHF | -2.62% | 151,491 |
Delayed Quote Swiss Exchange, January 16, 2026 at 01:14 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
27.02CHF
Average target price
32.80CHF
Spread / Average Target
+21.39%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- KURN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition